List view / Grid view
5 May 2021 | By Giovanni Di Guardo DVM Dipl. ECVP
Giovanni Di Guardo, DVM, Dipl. ECVP, retired Veterinary Pathologist, discusses the association between adenoviral vector COVID-19 vaccines and rare blood clots, outlining four areas warranting further research.
17 April 2025 | By Alistair Henry (UCB)
The rise of AI, digital twins, and advanced computational modelling signals a paradigm shift in pharmaceutical R&D. These advances are poised to challenge long-standing methodologies, demanding a workforce capable of navigating an evolving technological landscape. Alistair Henry, UCB’s Chief Scientific Officer, examines how the sector needs to embrace the shift…
19 April 2021 | By Hannah Balfour (European Pharmaceutical Review)
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
21 July 2020 | By Hannah Balfour (European Pharmaceutical Review)
Investigators report CanSino Biologics’ Ad5-nCoV vaccine induced antibody production with mild to moderate side effects in patients.
26 May 2020 | By Hannah Balfour (European Pharmaceutical Review)
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
10 June 2021 | By Hannah Balfour (European Pharmaceutical Review)
Trial shows the single-shot Janssen COVID-19 Vaccine generates robust immune responses against several COVID-19 variants.
4 February 2021 | By Victoria Rees (European Pharmaceutical Review)
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
15 September 2021 | By Anna Begley (European Pharmaceutical Review)
Johnson & Johnson’s Ebola vaccine regimen, Zabdeno® and Mvabea®, generated robust humoral immune responses in adults and children.
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-300x278.jpg)
![Moderna COVID-19 vaccine vials [Credit: Giovanni Cancemi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1893225814-400x187.jpg)
16 September 2021 | By Anna Begley (European Pharmaceutical Review)
New data shows that Moderna’s COVID-19 vaccine protects against variants of concern and reduces breakthrough infection risk.
15 July 2015 | By Victoria White
Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV...
1 October 2015 | By nanoString
The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…
18 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia...
24 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory diseases...
26 August 2013 | By Sanofi Pasteur
“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
